No.15, Lane 88 Wuwei Road, Putuo District, Shanghai
Tel: (+86) 021-50498986
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company incorporated in the State of Delaware, United States and developing products for the eye care market. Its shares are traded on the New York Stock Exchange, MKT market under the symbol: NBY. We commenced business relationship with NovaBay in 2012 and were granted the exclusive right to market, promote and sell its NeutroPhase® Skin and Wound Cleanser products in China and certain Southeast Asia markets. On October 2012, Mr. Li was appointed by NovaBay Board of Directors as the Asia-Pacific Advisor to its Board. On April 2015, Mr. Li was appointed by NovaBay Board of Directors as a Director to its Board.
To further enhance our business cooperation with NovaBay, with a view to maintaining our established relationship and improving our Company’s prospects for renewing or extending our exclusive right granted by NovaBay, We have completed several rounds of investment in NovaBay since 2013. As of the Lasted Practicable Date, we held approximately 34.1% equity interest in NovaBay.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription Avenova® lid and lash hygiene for the eye care market. Avenova is formulated with Neutrox™, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure hypochlorous acid. Laboratory tests show that pure hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and neutralizes bacterial toxins. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct medical salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. For additional information, visit: www.novabay.com
NovaBay’s Four Business Units
The Company’s four core business units – DermaBay, UroBay, EyeBay and MediBay – are developing treatments that tackle infections in the Dermatology, Urology, Ophthalmology, and Wound Care areas.
NovaBay’s first-in-class Aganocide compounds, led by auriclosene, are patented, topical antimicrobials with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides are not subject to bacterial or fungal resistance, which has been demonstrated in in vitro and in vivo studies. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, auriclosene is well suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on the following three disease areas:
Dermatology: Partnered with Galderma, a leading dermatology company, to develop a formulation of auriclosene for the treatment of highly contagious skin infection, impetigo, which occurs most commonly in children. Global Phase 2b clinical study is underway.
Ophthalmology: NovaBay is developing an eye drop formulation of auriclosene for treating adenoviral conjunctivitis, a highly contagious viral eye infection for which there is no approved treatment. Global Phase 2b clinical study is underway.
Urology: NovaBay announced in September2013 positive top-line results from its Phase 2 clinical study CL1001 forauriclosene (NVC-422) to prevent urinary catheter blockage and encrustation(UCBE) of indwelling urinary catheters. Based on these study results, theCompany plans to continue discussions with the US Food and Drug Administration.
Distinct from NovaBay’s Aganocides drug platform, NeutroPhase Skin and Wound Cleanser has been cleared by the U.S. Food and Drug Administration as a 510(k) medical device and is indicated as a skin and wound irrigant and cleanser. NeutroPhase, which targets the 6 million-patient U.S. market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers, is the only pure hypochlorous acid solution available today. For additional information, visit: www.neutrophase.com